Advanced search
1 file | 24.90 MB Add to list

Exploring the potential of [18F]AlF-PSMA-11 for prostate cancer imaging

Sarah Piron (UGent)
(2023)
Author
Promoter
(UGent) and (UGent)
Organization
Abstract
In men, prostate cancer (PCa) is the second most frequently occurring cancer and the fifth leading cause of cancer death. A major issue in the clinical management of PCa is the early detection of recurrent disease after radical prostatectomy or local therapy with curative intent. Approximately 30% of patients experience biochemical recurrence within ten years. For salvage therapy to be successful, the detection of recurrent disease and the precise localization of metastases is necessary to determine the most appropriate treatment. Positron emission tomography (PET) imaging allows to detect functional alternations before any morphological changes occur. Therefore, there is an increasing interest in reliable imaging biomarkers to accurately visualize the disease. Prostate specific membrane antigen (PSMA) is a promising target for the development of PET radioligands because of its overexpression on PCa cells. [18F]AlF-PSMA-11 was evaluated as a PSMA targeting PET tracer in a preclinical and clinical setting. In vivo experiments in PCa xenograft bearing mice allowed to extensively evaluate the influence of the molar activity and PSMA expression level on the biodistribution and tumor uptake of [18F]AlF-PSMA-11. These results highlighted the importance of taking into account the molar activity in PSMA imaging and its potential use in reducing uptake in dose-limiting organs during PSMA radioligand therapy. Comparing [18F]AlF-PSMA-11 to other PSMA radiotracers [68Ga]PSMA-11 and [18F]PSMA-1007 suggested [18F]AlF-PSMA-11 to be a suitable PSMA PET tracer. The phase I clinical trial demonstrated the safety and low radiation burden of [18F]AlF-PSMA-11. The following phase II clinical trial determined the recommended scan protocol to be imaging for 3 min/bed position at 1h post 2 MBq [18F]AlF-PSMA-11/kg body weight administration. Meanwhile, [18F]AlF-PSMA-11 has been successfully introduced into routine clinical practice and readily available for patient care.

Downloads

  • Doctoraatsthesis.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 24.90 MB

Citation

Please use this url to cite or link to this publication:

MLA
Piron, Sarah. Exploring the Potential of [18F]AlF-PSMA-11 for Prostate Cancer Imaging. Ghent University. Faculty of Pharmaceutical Sciences, 2023.
APA
Piron, S. (2023). Exploring the potential of [18F]AlF-PSMA-11 for prostate cancer imaging. Ghent University. Faculty of Pharmaceutical Sciences, Ghent, Belgium.
Chicago author-date
Piron, Sarah. 2023. “Exploring the Potential of [18F]AlF-PSMA-11 for Prostate Cancer Imaging.” Ghent, Belgium: Ghent University. Faculty of Pharmaceutical Sciences.
Chicago author-date (all authors)
Piron, Sarah. 2023. “Exploring the Potential of [18F]AlF-PSMA-11 for Prostate Cancer Imaging.” Ghent, Belgium: Ghent University. Faculty of Pharmaceutical Sciences.
Vancouver
1.
Piron S. Exploring the potential of [18F]AlF-PSMA-11 for prostate cancer imaging. [Ghent, Belgium]: Ghent University. Faculty of Pharmaceutical Sciences; 2023.
IEEE
[1]
S. Piron, “Exploring the potential of [18F]AlF-PSMA-11 for prostate cancer imaging,” Ghent University. Faculty of Pharmaceutical Sciences, Ghent, Belgium, 2023.
@phdthesis{01GQQGNF1MMY6GSW6F4D4M665K,
  abstract     = {{In men, prostate cancer (PCa) is the second most frequently occurring cancer and the fifth leading cause of cancer death. A major issue in the clinical management of PCa is the early detection of recurrent disease after radical prostatectomy or local therapy with curative intent. Approximately 30% of patients experience biochemical recurrence within ten years. For salvage therapy to be successful, the detection of recurrent disease and the precise localization of metastases is necessary to determine the most appropriate treatment. Positron emission tomography (PET) imaging allows to detect functional alternations before any morphological changes occur. Therefore, there is an increasing interest in reliable imaging biomarkers to accurately visualize the disease. Prostate specific membrane antigen (PSMA) is a promising target for the development of PET radioligands because of its overexpression on PCa cells. [18F]AlF-PSMA-11 was evaluated as a PSMA targeting PET tracer in a preclinical and clinical setting. In vivo experiments in PCa xenograft bearing mice allowed to extensively evaluate the influence of the molar activity and PSMA expression level on the biodistribution and tumor uptake of [18F]AlF-PSMA-11. These results highlighted the importance of taking into account the molar activity in PSMA imaging and its potential use in reducing uptake in dose-limiting organs during PSMA radioligand therapy. Comparing [18F]AlF-PSMA-11 to other PSMA radiotracers [68Ga]PSMA-11 and [18F]PSMA-1007 suggested [18F]AlF-PSMA-11 to be a suitable PSMA PET tracer. The phase I clinical trial demonstrated the safety and low radiation burden of [18F]AlF-PSMA-11. The following phase II clinical trial determined the recommended scan protocol to be imaging for 3 min/bed position at 1h post 2 MBq [18F]AlF-PSMA-11/kg body weight administration. Meanwhile, [18F]AlF-PSMA-11 has been successfully introduced into routine clinical practice and readily available for patient care.}},
  author       = {{Piron, Sarah}},
  language     = {{eng}},
  pages        = {{319}},
  publisher    = {{Ghent University. Faculty of Pharmaceutical Sciences}},
  school       = {{Ghent University}},
  title        = {{Exploring the potential of [18F]AlF-PSMA-11 for prostate cancer imaging}},
  year         = {{2023}},
}